Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSC vs FP in Persistent Asthma
NCT00452699Phase 4Completed
- Sponsor
- GSK
- Start
- May 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial of salmeterol in asthma (2 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Pre-dose FEV1 at 52 weeks. Started May 2007; status: completed.
02
Drugs
salmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00452699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452699.